Noladin ether, a putative endocannabinoid, inhibits μ-opioid receptor activation via CB2 cannabinoid receptors

Neurochemistry International

Volumn 52, Issue 1, 2008, Pages 321-328

  Páldyová, Estera ^a   Bereczki, Erika ^a   Sántha, Miklós ^a   Wenger, Tibor ^b   Borsodi, Anna ^a   Benyhe, Sándor ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Opioid receptor; 35S GTP S binding; Cannabinoid receptors; CB1 receptor knockout mouse; Forebrain; Noladin ether; Radioligand binding; Real time PCR; SR144528

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); MESSENGER RNA; MU OPIATE RECEPTOR; NOLADIN ETHER; OPIATE; OPIATE RECEPTOR; RADIOLIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; FOREBRAIN; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TRANSGENIC MOUSE;

ANIMALS; BASE SEQUENCE; DNA PRIMERS; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; GLYCERIDES; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); MICE; MICE, TRANSGENIC; POLYMERASE CHAIN REACTION; RADIOLIGAND ASSAY; RECEPTOR, CANNABINOID, CB2; RECEPTORS, OPIOID, MU; RNA, MESSENGER;

MUS; MUS MUSCULUS;

EID: 36849037426     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2007.06.033     Document Type: Article

References (44)

1. Arvidsson U., Riedl M., Chakrabarti S., Lee J.H., Nakano A.H., Dado R.J., Loh H.H., Law P.Y., Wessendorf M.W., and Elde R. Distribution and targeting of a μ-opioid receptor (MOR1) in brain and spinal cord. J. Neurosci. 15 (1995) 3328-3341
2. Benyhe S., Farkas J., Tóth G., and Wollemann M. Met5-enkephalin-Arg6-Phe7, an endogenous neuropeptide, binds to multiple opioid and nonopioid sites in rat brain. J. Neurosci. Res. 48 (1997) 249-258
3. Buckley N.E., McCoy K.L., Mezey E., Bonner T., Zimmer A., Felder C.C., Glass M., and Zimmer A. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur. J. Pharmacol. 396 (2000) 141-149
4. Demuth D.G., and Molleman A. Cannabinoid signaling. Life Sci. 78 (2006) 549-563
5. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., and Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
6. i/o linked receptor. Br. J. Pharmacol. 142 (2004) 509-518
7. Fezza F., Bisogno T., Minassi A., Appendino G., Mechoulam R., and Di Marzo V. Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and sensitive method for its quantification in rat tissues. FEBS Lett. 513 (2002) 294-298
8. Fotiadis D., Liang Y., Filipek S., Saperstein D.A., Engel A., and Palczewski K. The G protein-coupled receptor rhodopsin in the native membrane. FEBS Lett. 564 (2004) 281-288
9. George S.R., O'Dowd B.F., and Lee S.R. G-protein-coupled receptor oligomerization and its potential for drug discovery. Nat. Rev. Drug Discov. 1 (2002) 802-820
10. Ghozland S., Matthes H.W.D., Simonin F., Filliol D., Kieffer B.L., and Maldonado R. Motivational effects of cannabinoids are mediated by μ-opioid and κ-opioid receptors. J. Neurosci. 22 (2002) 1146-1154
11. Gong J.-P., Onaivi E.S., Ishiguro H., Liu Q.-R., Tagliaferro P.A., Brusco A., and Uhl G.R. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res. 1071 (2006) 10-23
12. Hanus L., Abu-Lafi S., Fride E., Breuer A., Vogel Z., Shalev D.E., Kustanovich I., and Mechoulam R. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl Acad. Sci. U.S.A. 98 (2001) 3662-3665
13. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., and Rice K.C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 1932-1936
14. Howlett A.C. Pharmacology of cannabinoid receptors. Ann. Rev. Pharmacol. Toxicol. 35 (1995) 607-634
15. Howlett A.C. The CB1 cannabinoid receptor in the brain. Neurobiol. Dis. 5 (1998) 405-416
16. Childers S.R., Fleming L., Konkoy C., Marckel D., Pacheco M., Sexton T., and Ward S. Opioid and cannabinoid receptor inhibition of adenylyl cyclase in brain. Ann. N Y Acad. Sci. 654 (1992) 33-51
17. Ishac E., Jiang L., Lake K., Varga K., Abood M., and Kunos G. Inhibition of exocytotic noradrenaline release by presynaptic CB1 receptors on peripheral sympathetic nerves. Br. J. Pharmacol. 118 (1996) 2023-2028
18. Kieffer B.L. Opioids: first lessons from knockout mice. Trends Pharmacol. Sci. 20 (1999) 19-26
19. 1 receptor knockout mice. Science 283 (1999) 401-404
20. Maldonado R., and Rodríguez de Fonseca F. Cannabinoid addiction: behavioral models and neuronal correlates. J. Neurosci. 22 (2002) 3326-3331
21. Mansour A., Fox C.A., Akil H., and Watson S.J. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci. 18 (1995) 22-29
22. Manzanares J., Corchero J., Romero J.J., Fernandez-Ruiz J.J., Ramos J.A., and Fuentes J.A. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol. Sci. 20 (1999) 287-293
23. Martin M., Ledent C., Parmentier M., Maldonado R., and Valverde O. Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice. Eur. J. Neurosci. 12 (2000) 4038-4046
24. Massi P., Vaccani A., Rubino T., and Parolaro D. Cannabinoids and opioids share cAMP pathway in rat splenocytes. J. Neuroimmunol. 145 (2003) 46-54
25. Matsuda L.A., Lolait S.J., Brownstein B.J., Young A.C., and Bonner T.L. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
26. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almong S., Martin B.R., Compton D.R., Pertwee R.G., Griffin G., Bayewitch M., Barg J., and Vogel Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50 (1995) 83-90
27. Mechoulam R., Fride E., Ben-Shabat S., Meiri U., and Horowitz M. Carbachol, an acetylcholine receptor agonist, enhances production in rat aorta of 2-arachidonoyl glycerol, a hypotensive endocannabinoid. Eur. J. Pharmacol. 362 (1998) R1-R3
28. Milligan G. G protein-coupled receptor dimerization: function and ligand pharmacology. Mol. Pharmacol. 66 (2004) 1-7
29. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
30. Navarro M., Carrera M.R.A., Fratta W., Valverde O., Cossu G., Fattore L., Chowen J.A., Gomez R., del Arco I., Villanúa M.A., Maldonado R., Koob G.F., and Rodríguez de Fonseca F. Functional interaction between opioid and cannabinoid receptors in drug self-administration. J. Neurosci. 21 (2001) 5344-5350
31. Oka S., Tsuchie A., Tokumura A., Muramatsu M., Suhara Y., Takayama H., Waku K., and Sugiura T. Ether-linked analogue of 2-arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species. J. Neurochem. 85 (2003) 1374-1381
32. Pertwee R.G. Cannabinoid receptors and pain. Prog. Neurobiol. 63 (2001) 569-611
33. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29 (2001) e45
34. Pickel V.M., Chan J., Kash T.L., Rodriguez J.J., and Mackie K. Compartment-specific localization of cannabinoid 1 (CB1) and mu-opioid receptors in rat nucleus accumbens. Neuroscience 127 (2004) 101-112
35. Puskas L.G., Bereczki E., Santha M., Vigh L., Csanadi G., Spener F., Ferdinandy P., Onody A., and Kitajka K. Cholesterol and cholesterol plus DHA diet-induced gene expression and fatty acid changes in mouse eye and brain. Biochimie 87 (2005) 239-1239
36. Reisine T., Law S.F., Blake A., and Tallent M. Molecular mechanisms of opiate receptor coupling to G proteins and effector systems. Ann. N Y Acad. Sci. 780 (1996) 168-175
37. Rinaldi-Carmona M., Barth F., Millan J., Derocq J.M., Casellas P., Congy Ch., Oustric D., Sarran M., Bouaboula M., Calandra B., Portier M., Shire D., Breliére J.C., and Le Fur G. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284 (1998) 644-650
38. Rios C., Gomes I., and Devi L.A. μ Opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br. J. Pharmacol. 148 (2006) 387-395
39. Rios C.D., Jordan B.A., Gomes I., and Devi L.A. G-protein-coupled receptor dimerization: modulation of receptor function. Pharmacol. Ther. 92 (2001) 71-87
40. Shoemaker J.L., Joseph B.K., Ruckle M.B., Mayeux P.R., and Prather P.L. The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors. J. Pharmacol. Exp. Ther. 314 (2005) 868-875
41. 35S]thio]-triphosphate binding. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 7242-7246
42. Sugiura T., Oka S., Gokoh M., Kishimoto S., and Waku K. New perspectives in the studies on endocannabinoid and cannabis: 2-arachydonoylglycerol as a possible novel mediator of inflammation. J. Pharmacol. Sci. 96 (2004) 367-375
43. 35S](thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol. Pharmacol. 47 (1995) 848-854
44. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., Stella N., Makriyannis A., Piomelli D., Davison J.S., Marnett L.J., Di Marzo V., Pittman Q.J., Patel K.D., and Sharkey K.A. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310 (2005) 329-332